XML 70 R61.htm IDEA: XBRL DOCUMENT
v3.25.1

Commitments and Contingencies - Additional Information (Details) - USD ($) |  |  | 1 Months Ended | 3 Months Ended |
--- | --- | --- | --- | --- | ---
May 13, 2021 | Dec. 02, 2020 | Sep. 30, 2020 | Mar. 31, 2025 | Mar. 31, 2024 | Oct. 31, 2016
Loss Contingencies [Line Items] |  |  |  |  |  |
Research and development |  |  |  | $ 2,870,000 | $ 2,040,000 |
Revenue Share Agreement | Oncimmune Limited |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |
Royalty expense |  |  |  | $ 400,000 | 200,000 |
Percentage of license agreement and royalty payment related to Nodify CDT test recognized revenue for non-screening tests |  |  |  | 8.00% |  |
Minimum annual volume percentage thereafter |  |  |  | 5.00% |  |
Bio-Rad License |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |
License fees |  |  |  | $ 0 |  |
License expiry date |  |  |  | 2024-08 |  |
CellCarta License |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |
Percentage of royalty payments on net revenue | 0.675% |  |  |  |  |
Percentage of fee payments on net sales | 1.00% |  |  |  |  |
Term of royalty payments from first commercial sale | 15 years |  |  |  |  |
Year of ending royalty payments from first commercial sale | 2034 |  |  |  |  |
Royalty expense |  |  |  | $ 100,000 | 100,000 |
AVEO Oncology |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |
Research and development |  |  |  | 0 | $ 0 |
Obligations related to agreement. |  |  |  | $ 0 |  |
AVEO Oncology | Ficlatuzumab |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |
Percentage of development and regulatory costs exercised using opt-out right |  |  | 50.00% |  |  |
Percentage of royalty payments on net sales |  | 10.00% |  |  |  |
Percentage of license income generated from licensing |  | 25.00% |  |  |  |
AVEO Oncology | NSCLC POC Trial |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |
Responsible percentage of development and regulatory costs |  |  |  |  |  | 50.00%

X
- Definition License agreement expiry date. + References No definition available. + Details
Name: | bdsx_LicenseAgreementExpiryDate
Namespace Prefix: | bdsx_
Data Type: | xbrli:gYearMonthItemType
Balance Type: | na
Period Type: | duration

X
- Definition License fees. + References No definition available. + Details
Name: | bdsx_LicenseFees
Namespace Prefix: | bdsx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Minimum annual volume percentage thereafter. + References No definition available. + Details
Name: | bdsx_MinimumAnnualVolumePercentageThereafter
Namespace Prefix: | bdsx_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Obligations related to agreement. + References No definition available. + Details
Name: | bdsx_ObligationsRelatedToAgreement
Namespace Prefix: | bdsx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Percentage of development and regulatory costs. + References No definition available. + Details
Name: | bdsx_PercentageOfDevelopmentAndRegulatoryCosts
Namespace Prefix: | bdsx_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Percentage of development and regulatory costs exercised using opt-out right. + References No definition available. + Details
Name: | bdsx_PercentageOfDevelopmentAndRegulatoryCostsExercisedUsingOptOutRight
Namespace Prefix: | bdsx_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of fee payments on net sales. + References No definition available. + Details
Name: | bdsx_PercentageOfFeePaymentsOnNetSales
Namespace Prefix: | bdsx_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of license income generated from licensing. + References No definition available. + Details
Name: | bdsx_PercentageOfLicenseIncomeGeneratedFromLicensing
Namespace Prefix: | bdsx_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of revenue share payment related to nodify cdt test recognized revenue for non-screening tests. + References No definition available. + Details
Name: | bdsx_PercentageOfRevenueSharePaymentRelatedToNodifyCdtTestRecognizedRevenueForNonScreeningTests
Namespace Prefix: | bdsx_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of royalty payments on net revenue. + References No definition available. + Details
Name: | bdsx_PercentageOfRoyaltyPaymentsOnNetRevenue
Namespace Prefix: | bdsx_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of royalty payments on net sales. + References No definition available. + Details
Name: | bdsx_PercentageOfRoyaltyPaymentsOnNetSales
Namespace Prefix: | bdsx_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Term of royalty payments from first commercial sale. + References No definition available. + Details
Name: | bdsx_TermOfRoyaltyPaymentsFromFirstCommercialSale
Namespace Prefix: | bdsx_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Year of ending royalty payments from first commercial sale. + References No definition available. + Details
Name: | bdsx_YearOfEndingRoyaltyPaymentsFromFirstCommercialSale
Namespace Prefix: | bdsx_
Data Type: | xbrli:gYearItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 720 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483359/720-20-50-1 Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 27 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482395/460-10-55-27 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482425/460-10-50-3 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1 + Details
Name: | us-gaap_LossContingenciesLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1 Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1 + Details
Name: | us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details
Name: | us-gaap_RoyaltyExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=bdsx_RevenueShareAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=bdsx_OncimmuneLimitedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bdsx_BioRadLicenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bdsx_CellCartaLicenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=bdsx_AVEOOncologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_EquitySecuritiesByIndustryAxis=bdsx_FiclatuzumabMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bdsx_NSCLCPOCTrialMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |